MXPA04011560A - Formulacion anti-cancer. - Google Patents

Formulacion anti-cancer.

Info

Publication number
MXPA04011560A
MXPA04011560A MXPA04011560A MXPA04011560A MXPA04011560A MX PA04011560 A MXPA04011560 A MX PA04011560A MX PA04011560 A MXPA04011560 A MX PA04011560A MX PA04011560 A MXPA04011560 A MX PA04011560A MX PA04011560 A MXPA04011560 A MX PA04011560A
Authority
MX
Mexico
Prior art keywords
rubidium
ursolate
ursolic acid
composition
mmp
Prior art date
Application number
MXPA04011560A
Other languages
English (en)
Inventor
Monroe Stephen
Original Assignee
Greystone Medical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greystone Medical Group Inc filed Critical Greystone Medical Group Inc
Publication of MXPA04011560A publication Critical patent/MXPA04011560A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Composicion para detener la metastasis de celulas de cancer que comprende rubidio ursolato. El rubidio ursolato se forma de una mezcla de rubidio y acido ursolico obtenido de la corteza de la planta Virburnum.

Description

FORMULACION ANTI-CANCER Esta invención se relaciona a formulaciones para la prevención o para detener la metástasis de células de cáncer.
DESCRIPCION DE LA INVENCION El ácido ursólico derivado de la corteza de la planta Viburnum ha sido reportado que tiene actividad antiinvasiva con células de fibrosarcoma humanas. El mecanismo de actividad fue reportado para ser ideado en envolver la regulación a la baja de MMP-9, una metaloprotexnasa de matriz que degrada gelatina. Ha sido además reportado que no hubo efecto sobre MMP-2, la segunda de dos MMP's que degradan gelatina.
De acuerdo con la presente invención, el Rubidio es combinado con ácido ursólico para hacer una sal del ácido, Rubidio Ursolato, que cuando se administra a un paciente, regula a la baja MMP-2 y MMP-9. Esta combinación de los dos inhibidores de MMP proporciona un tratamiento para de-tener el esparcimiento o metástasis de las células de cáncer, en general .

Claims (7)

REIVINDICACIONES
1. Una composición para detener la metástasis de células de cáncer que comprende cantidades farmacéuticamente eficaces de rubidio ursolato.
2. La composición de conformidad con la reivindicación 1, en donde la composición, cuando se administra a un paciente, regula a la baja el MMP-2 y MMP-9.
3. La composición de conformidad con la reivindicación 1, en donde el rubidio ursolato se forma de una mezcla de rubidio y ácido ursólico.
4. La composición de conformidad con la reivindicación 3, en donde el ácido ursólico se obtiene -de la corteza de la planta Virburnum.
5. Un método para detener la metástasis de células de cáncer que comprende administrar a un paciente en necesidad de la misma, una cantidad farmacéuticamente eficaz de rubidio ursolato.
6. El método de conformidad con la reivindicación 5, en donde el rubidio ursolato se forma de una mezcla de ácido ursólico y rubidio.
7. El método de conformidad con la reivindicación 5, en donde el ácido ursólico se deriva de la corteza de la planta Virburnum.
MXPA04011560A 2002-05-24 2003-05-22 Formulacion anti-cancer. MXPA04011560A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38246002P 2002-05-24 2002-05-24
PCT/US2003/016188 WO2003099218A2 (en) 2002-05-24 2003-05-22 Anti-cancer formulation

Publications (1)

Publication Number Publication Date
MXPA04011560A true MXPA04011560A (es) 2005-06-08

Family

ID=29584412

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04011560A MXPA04011560A (es) 2002-05-24 2003-05-22 Formulacion anti-cancer.

Country Status (7)

Country Link
US (1) US20040023937A1 (es)
EP (1) EP1507542A4 (es)
JP (1) JP2005527613A (es)
AU (1) AU2003248555A1 (es)
CA (1) CA2486704A1 (es)
MX (1) MXPA04011560A (es)
WO (1) WO2003099218A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660012A4 (en) * 2003-08-25 2008-04-30 Greystone Medical Group Inc CELLULAR DEPOLARISATION AND REGULATION OF MATRIX METALLOPROTEINASES
US20100260863A1 (en) * 2007-12-11 2010-10-14 Monroe Stephen H Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
DE102009012561B4 (de) * 2009-03-11 2015-01-22 Rohde & Schwarz Gmbh & Co. Kg Verfahren und Mobilfunktester zur Erzeugung einer global gültigen Adresse für ein Mobilfunkgerät für eine Mobilfunk-Testprozedur
CN103923159B (zh) * 2014-04-24 2016-04-27 长沙麓园生物科技有限公司 一种从枇杷叶中提取精制熊果酸的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT73791A (en) * 1992-11-06 1996-09-30 H E Stanley Pharmaceuticals Compositions of oak bark extract, related synthetic compositions, and method of using same
JP3041232B2 (ja) * 1995-11-16 2000-05-15 日本ケミカルリサーチ株式会社 癌転移抑制剤
US5932617A (en) * 1998-02-06 1999-08-03 Woundfast Pharmaceuticals Inc. Wound-treating composition and method
AU7350500A (en) * 1999-08-31 2001-03-26 Brian C. Giles Method and formula for tumor remission and suppression of cancer
AU2002224595A1 (en) * 2000-07-31 2002-02-13 The Nisshin Oil Mills, Ltd. Antitumor agents
US20030133991A1 (en) * 2001-11-29 2003-07-17 Greystone Medical Group, Inc. Treatment of wounds and compositions employed

Also Published As

Publication number Publication date
WO2003099218A3 (en) 2004-04-08
AU2003248555A1 (en) 2003-12-12
JP2005527613A (ja) 2005-09-15
WO2003099218A2 (en) 2003-12-04
EP1507542A4 (en) 2008-01-23
US20040023937A1 (en) 2004-02-05
CA2486704A1 (en) 2003-12-04
EP1507542A2 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
AU2020286177A1 (en) Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
Tradati et al. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR)
RU2605279C2 (ru) Применяемые местно стронцийсодержащие комплексы для лечения боли, зуда и воспаления
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
CA2484514A1 (en) Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
MY124648A (en) Inhibitor of factor xa alone or in combination with an anti-platelet aggregation agent, for combating arterial thrombosis.
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
JP2006516571A5 (es)
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
JP2018537503A (ja) 末梢神経障害を治療するための方法及び組成物
AR026257A1 (es) N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen
MXPA04011560A (es) Formulacion anti-cancer.
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
GEP20043231B (en) Resorcinol Composition
EP1550443A4 (en) COMPOSITION AGAINST STRESS-BASED DISEASES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal